NCT00161031View on ClinicalTrials.gov

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Schizophrenia
Interventions
DRUG

Atomoxetine

Trial Locations (2)

21228

Veterans Affairs Maryland Health Care System, Baltimore

Maryland Psychiatric Research Center, Catonsville

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT00161031 - Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia | Biotech Hunter | Biotech Hunter